Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“The Family Smoking Prevention and Tobacco Control Act (TCA) requires the FDA to authorize the marketing of new tobacco products within 180 days of receipt of an application.”
UnverifiableConfidence: LOW

Reasoning

The evidence from Reason.com cites the Family Smoking Prevention and Tobacco Control Act (TCA) as expressly requiring the FDA to authorize (grant or deny) marketing of new tobacco products within 180 days of receiving an application. This aligns precisely with the claim.

On confidence: The provided excerpts directly quote the statute's requirement that the FDA must grant or deny new product applications no later than 180 days after receipt.

Important context

The statute sets a deadline of 180 days for the FDA to act on new tobacco product applications, but the excerpts also note that the agency has historically failed to meet this deadline.

Evidence

Supporting (2)

Limitations

The evidence is limited to secondary reporting from a news outlet; the original statutory text was not directly quoted. No additional sources were consulted. No independent origin corroborated this claim, so it cannot be verified and confidence cannot be high.

Last verified:
Oct 1, 2026, 4:40 AM CDT
Pipeline:
2.1.0
Claim type:
Factual

Where this claim appeared

The FDA Promises To Streamline the Dauntingly Complex Rules for Approving Nicotine Products

Reason · Jacob Sullum